Acuvi AB ("Acuvi" or the "Company") recently completed a fully guaranteed rights issue of shares amounting to approximately SEK 27.8 million before issue costs (the "Rights Issue"). The subscription period for the Rights Issue ended on June 20, 2024. A total of 2,615,530 shares were subscribed for, with and without the support of subscription rights, corresponding to approximately 122 percent of the Rights Issue.

Acuvi’s full press release can be found here.

Acuvi’s CEO, Olof Stranding, comments:
"I am pleased to see the strong interest in subscribing to the rights issue. In today's market climate, successfully completing an oversubscribed issue without a discount is a sign of strength. I also want to take this opportunity to welcome our new shareholder, ShapeQ, to Acuvi. For Acuvi, it is important to bring in more long-term shareholders who recognize the company's potential."

About Acuvi
The demand for ever-increasing precision is growing in fields such as medical technology, the semiconductor industry, and automation. Acuvi provides unique technologies and advanced systems to support this development. The company's customers manufacture, for example, surgical robots, semiconductor production equipment, and diagnostic systems. Acuvi has a local presence in both Europe and the U.S. The company’s headquarters are located in Uppsala. Acuvi’s shares are traded on Nasdaq First North Growth Market.

Corpura Fondkommission acted as financial advisor in connection with the Rights Issue.

For more information contact:
Carl Kindal
Phone: +46(0)73-501 58 58
E-mail: carl.kindal@corpura.se

‍